Jpmorgan Chase & CO Bio Xcel Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BTAI
# of Institutions
55Shares Held
3.14MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$684,7840.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$251,1900.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$169,8840.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$105,4830.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$74,0250.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $16M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...